Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
2017 · The Lancet · 433 citations
https://doi.org/10.1016/s0140-6736(17)33108-2
O
Olivier Casasnovas
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
633
Papers
24.5K
Citations
86
h-index
255
i10-index
Olivier Casasnovas is an academic researcher from Inserm. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & Viral-associated cancers and disorders. The author has an h-index of 86, co-authored 539 publications.
ORCID: 0000-0002-1156-8983Papers by this author
worksRituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
2017 · New England Journal of Medicine · 402 citations
https://doi.org/10.1056/nejmoa1701769
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
2016 · The Lancet · 390 citations
https://doi.org/10.1016/s0140-6736(16)00739-x
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
2022 · Nature Medicine · 355 citations
https://doi.org/10.1038/s41591-022-01969-y
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
2021 · Nature Biotechnology · 343 citations
https://doi.org/10.1038/s41587-021-00981-w
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†
2020 · Annals of Oncology · 194 citations
https://doi.org/10.1016/j.annonc.2020.11.019
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat